President Sean Tunis (United States), 2017-19
Sean Tunis, MD, MSc, is the Founder, President and Chief Executive Officer of the Center for Medical Technology Policy (CMTP) in Baltimore, Maryland. CMTP is an independent, non-profit organization that provides a neutral platform for multi-stakeholder collaborations that are focused on improving the quality, relevance and efficiency of clinical research. His work currently focuses on expanding infrastructure for the conduct of pragmatic clinical trials within the health care delivery systems, developing condition-specific evidentiary standards for reimbursement, and promoting greater engagement of patients and consumers in clinical research. Tunis serves on the Board of HTAi, the Health Sciences Policy Council for ISPOR and a number of other advisory boards for public and private sector organizations focused on issues of comparative effectiveness, innovation, health technology assessment, evidence-based medicine, clinical research and reimbursement.
Vice-President Iñaki Gutierrez-Ibarluzea (Spain), 2017-19
BSc and MSc in Sciences from the University of the Basque Country UPV-EHU, Doctor in Sciences (NeuroScience) from the same university, Masters in Epidemiology from the University of Granada and the Andalusian School of Public Health and Masters in Bioethics from the University Ramon Llul and the Institute Borja of Bioethics. He is the coordinator of the early warning and alert system on new and emerging health technologies of Osteba, Basque Office for Health Technology Assessment. Iñaki is the co-chair of the HTAi IG on Disinvestment and Early Awareness, and a member of the information resources IG of HTAi and the liaison person of the Public Health and Nutrition IG. He has collaborated on the European Union funded projects such as InnoHTA (Innovation and HTA), EUnetHTA (European Network for HTA), PHGEN I and II (Public Health Genomics) ALCOVE (Alzheimer in Europe), PerMed (Personalised Medicine), DISCHARGE and Health Cluster Network, performing different functions. He has also coordinated various projects at the Spanish level such as: GENTecS (Group for the Evaluation of New Technologies in Health) and the Information Resources group.
He was a member of the Board of Directors (2010-2012) and Secretary of the International Society HTAi (2012-2014). He has been the chairman of EuroScan International Network for the identification and evaluation of new and emerging health technologies in the period (2007-2010), vice-chair in the periods (2005-2007) and (2010-2011). He is currently the Vice Chair of EuroScan. Iñaki is also an associated professor in the School of Nursing of Osakidetza Basque Health Service and works with the University of the Basque Country and the Open University of Catalonia in different academic activities. He has also participated as an advisor in different call for funds at the local, regional, country (Spain, Poland, Korea and UK) and the European Union levels (FP7, COST and Horizon 2020). He has been a member of the International Scientific Committee of the Health Innovation Awards of the NHS-North West 2009 (United Kingdom).
He has collaborated with the Spanish Ministry of Industry and the Spanish Observatory for Prospective Technological Studies and is a member and coordinator of the Task Force for Genomics and Public Health. He has also participated as expert advisor in the forum for social cohesion between the EU and Mexico (2010). Recently, he has collaborated with WHO-Europe as expert advisor and evaluator on the program of Medical Devices for Countries with limited resources. Iñaki has been advising different HTA initiatives in Argentina, Brazil, Colombia, Costa Rica, Mexico, South Africa, Tunisia, Israel, the Horizon Scanning initiative of EEUU and Italy, WHO-EMRO region, WHO health technologies unit and is member of the HTA glossary committee. As member of the Basque Ministry of Health Iñaki has relevant experience on Chronic diseases and its management (http://ec.europa.eu/research/innovation-union/pdf/active-healthy-ageing/basque.pdf). In 2016 he served as co-chair of the ISPC of HTAi Tokyo 2017 and he has been member or the ISPCs in HTAi Oslo.
Treasurer Marco Marchetti (Italy), 2018-20
Marco Marchetti graduated in medicine at Università Cattolica del Sacro Cuore (Rome) and postgraduate in Hygiene and Public Health and Legal Medicine.
Since January 1, 2017, he has been the Director of the National Center for the Health Technology Assessment of the Italian National Institute for Health.
He was Director of the Health Technology Assessment and Innovation Unit of the Fondazione Policlinico Universitario “Agostino Gemelli” at the Università Cattolica del Sacro Cuore until December 2016. He has also been the European Director of the International Master Program in HTA and Management since 2001.
He has been in the period 2007-2015 Director of Scientific-Technical Office of Institutional review board (IRB) – Ethical review board of the Università Cattolica del Sacro Cuore .
He has been assistant to Medical Director of the Policlinico Universitario “Agostino Gemelli” at the Università Cattolica del Sacro Cuore from February 1995 to January 2001.
He has been an expert and referee for Health Technology research proposals in 2003 and 2008 through the NHS Health Technology Assessment Programme, of the National Coordinating Office for Health Technology Assessment in the United Kingdom.
He was in charge of organizing the second HTAi Annual Meeting, “Bringing HTA into Practice,” in June 2005, and was Co-Chair of Local Organizing Committee of the 2017 HTAi Annual Meeting in Rome in June 2017. He is Co-Chair of the HTAi Interest Group Hospital-Based HTA. Since the beginning, he has participated ino the activities of the European Network of Health Technology Assessment.
His areas of expertise are in the following fields: hospital management, quality assurance, risk management, HTA, drug epidemiology, evidence-based medicine and digital medicine impact evaluation. He has collaborated with the National Agency for Drugs and Regional Government in the assessment process of different drugs and medical devices with a particular focus on innovative pricing scheme and payment by results. He has published more than 150 papers on national and international on the subjects he interested in.
Secretary Franz Pichler (Australia), 2018-20
Franz Pichler is a Senior Director in the Global Public Policy group at Eli Lilly and company. He specializes on international health care policy issues relating to Health Technology Assessment (HTA). He supports regional market access policy in Japan, where he chairs the PhRMA Japan Vision Task Force, and in China, where he co-chairs the HTA Working Group of the China R&D Based Pharmaceutical Association Committee (RDPAC). Previously, he has worked on the European HTA policy, including representing Lilly on the EFPIA HTA Working Group, EuropaBio HTA and Market Access Group and as a participant of the IMI GetReal public-private partnership.
Franz has been an active member of HTAi for over ten years. In 2012, Franz co-founded the HTA-Regulatory Interactions Interest Group and chaired this IG until its merger to form the Regulatory Interactions and Conditional Coverage (RICC) Interest Group in 2016. He currently chairs the Business Development Group and is a member of the Scientific Development and Capacity Building (SDCB) Committee and the Asia Policy Forum Organising Committee (APFOC).
Franz joined Lilly in 2012 after serving as the manager of the HTA Programme at the Centre for Innovation in Regulatory Science (CIRS), a non-profit, independent medicines policy and research think tank. Prior to joining CIRS, Franz worked for over 10 years in molecular biology with specialties in functional genomics, population genetics and bioinformatics. He obtained his BSC in biology and PhD in population genetics at the University of Auckland in 1997 and 2002, respectively.